Zai Lab Ltd (ZLAB) company profile
Close on Nov 17, 2026Market cap $3.65BP/E –Yield –
About Zai Lab
Pharmaceutical Preparations, SIC 2834
Zai Lab is a commercial-stage biopharmaceutical company that develops and commercializes therapies for oncology, autoimmune disorders, neuroscience, and infectious diseases. Its commercial portfolio features licensed therapies including ZEJULA for ovarian cancer, VYVGART and VYVGART Hytrulo for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, NUZYRA for pneumonia and skin infections, and OPTUNE for glioblastoma. The company also markets QINLOCK for gastrointestinal stromal tumors, XACDURO for hospital-acquired bacterial infections, and AUGTYRO for solid tumors and non-small cell lung cancer. Its customers include medical centers, distributors, and adult patients requiring specialized treatments.
Geographically, the company maintains operations in Greater China and the United States, with commercial sales teams covering major medical centers in mainland China, Hong Kong, Macau, and Taiwan. The business operates seven approved commercial programs alongside internal research and development activities and clinical trial collaborations across China and the United States. The provided text does not state the location of its corporate headquarters.
Summary of the business section of Zai Lab's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Zai Lab Ltd
- Headquarters
- Shanghai, China
- Address
- 899 Halei Road, Building B, Pudong
- Phone
- 862161632588
- Website
- zailaboratory.com
- Employees
- 1,784, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- E9
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Short Hills, New Jersey
Stock & identifiers
- Ticker
- ZLAB
- Exchange
- Nasdaq
- IPO date
- Sep 21, 2017
- Shares outstanding
- 1.55B, Jul 31, 2026
- Public float
- $3.80B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 10-for-1, Mar 30, 2022
- SEC CIK
- 1704292
- CUSIP
- 98887Q104
- ISIN
- US98887Q1040
- FIGI
- BBG00HFX3N90
- Share class FIGI
- BBG00HFX3P04
- LEI
- 549300P2UYQ9U5LY1T58
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ying Du | Chairperson & CEO, Director | 1,226,224 |
| Yajing Chen | Chief Financial Officer | 36,240 |
| Frazor Titus Edmondson III | Chief Legal Officer | 30,346 |
| Yizhe Wang | Operating Partner | – |
| Joshua L. Smiley | See Remarks | 117,602 |
| Rafael Amado | See Remarks | 57,022 |
| Richard Gaynor | Director | 81,965 |
| William Lis | Director | 41,931 |
| Michel Vounatsos | Director | 72,787 |
| Scott W. Morrison | Director | 56,904 |
| John D. Diekman | Director | 122,140 |
| Leon O. Moulder Jr | Director | 94,973 |
| Peter Wirth | Director | 420,121 |
| Nisa Leung | Director | 8,019,229 |
| Kai-Xian Chen | Director | 39,525 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $10.68M | $1.86M | $3.80M | $13 | $125 |
| FY2024 | $9.08M | $12.07M | $3.62M | $19 | $93 |
| FY2023 | $12.04M | $7.52M | $3.89M | $20 | $94 |
| FY2022 | $20.21M | $739.60K | $6.84M | $23 | $90 |
| FY2021 | $15.32M | -$30.50M | $6.18M | $46 | $100 |
| FY2020 | $8.54M | $112.74M | $3.40M | $325 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Samantha (Ying) Du Chief Executive Officer and Chairperson of the Board of Directors | $908.73K | $3.23M | $5.82M | $695.18K | $17.50K | $10.68M | +18% |
| Yajing Chen Chief Financial Officer | $520.00K | $1.21M | $1.23M | $205.92K | $17.50K | $3.19M | +21% |
| Rafael Amado President, Head of Global Research and Development | $641.70K | $1.51M | $1.54M | $298.39K | $17.50K | $4.01M | +10% |
| F. Ty Edmondson Chief Legal Officer and Corporate Secretary | $590.88K | $1.21M | $1.23M | $233.99K | $17.50K | $3.28M | +19% |
| Josh Smiley President and Chief Operating Officer | $672.75K | $1.81M | $1.85M | $347.14K | $17.50K | $4.70M | -14% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Sep 21, 2017
- Offer price
- $18.00
- Securities offered
- 8,333,333
- Gross proceeds
- $150.00M
- Exchange
- Nasdaq
- First trading day
- Sep 20, 2017
- Lock-up ends (est.)
- Mar 19, 2018
“The initial public offering price is $18.00 per ADS.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of January 31, 2026, we had 1,784 full-time employees, of which 1,710 were located in Greater China.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 1, 2022 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| May 2, 2022 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Apr 21, 2022 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Sep 21, 2017 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 14, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?